復星醫藥(02196.HK)向非全資附屬醫療機構增資1,020萬人幣
復星醫藥(02196.HK)公布,公司附屬復星健康,星雙健投資及復星健控擬按照各自所持上海卓瑞股權比例向其增資共2,000萬元人民幣(下同),三方分別出資1,020萬元、490萬元和490萬元。控股股東復星高科技通過星雙健投資及復星健控,間接合計持有上海卓瑞49%股權。
上海卓瑞為營利性醫療機構,主要通過引進國內外醫療資源,提供體檢、全科、專科門診等醫療服務,為公司非全資附屬公司。增資後,復星健康、星雙健投資、復星健控對上海卓瑞持股比例維持在 51%、24.5%和24.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.